Abstract
Our clinical case for discussion is about a short statured boy who was 14.6 years old at his first evaluation. He was born after a 39-week gestation as the third child of a non-consanguineous marriage. His birth weight was 3.250 g (−0.3 SDS), and his birth length was not available. His neuropsychomotor development was normal, his school performance was good, and there were no remarkable findings in his medical history. His father’s height was 174 cm (−0.1 SDS) and his mother’s height was 154 cm (−1.3 SDS), resulting in a target height of 170.6 cm (−0.6 SDS). His father and mother apparently had normal pubertal development, and his mother’s age of menarche was 13 years old. His older brother’s height was not available, but he had a previous history of pubertal spurt after 16 years of age. Likewise, his older sister’s height was also not available, but she had a previous history of menarche at 14.
Competing Interests Statement: The authors declare that they have no competing financial interests.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jorge AAL, Arnhold IJP. Normal growth and short stature. In: Saad MAJ, Maciel RMB, Mendonca BB, editors. Endocrinology. São Paulo: Atheneu; 2007. p. 187–226.
Wit JM, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P. Idiopathic short stature: definition, epidemiology and diagnostic evaluation. Growth Horm IGF Res. 2008;18:89–110.
Reiter EO, Rosenfeld RG. Normal and aberrant growth. In: Kronenberg MH, Melmed S, Polonsky KS, Larsen PR, editors. Williams textbook of endocrinology. 11th ed. Philadelfia: Saunders Elsevier; 2007. p. 849–968.
Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metabol. 2008;93(11):4210–7.
Oostdijk W, Grote FK, Muinck Keizer-Schrama SMPF, Wit JM. Diagnostic approach in children with short stature. Horm Res. 2009;72:206–17.
Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44(235):291–303.
Marshall WA, Tanner JM. Variations in pattern of pubertal changes in boys. Arch Dis Child. 1970;45(239):13–23.
Gerver WJ, Bruin R. Paediatric morphometrics—a reference manual. Maastricht: UniversitairePers Maastricht; 2001.
Kant SG, Grote F, de Ru MH, Oostdijk W, Zonderland HM, Breuning MH, Wit JM. Radiographic evaluation of children with growth disorders. Horm Res. 2007;68:310–5.
Greulich WW. Pyle SI radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford, CA: Stanford UniversityPress; 1959.
Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952;40:423.
Jorge AAL. Baixa estatura por deficiência de hormônio de crescimento: diagnóstico. In: Jatene FB, Nobre MRC, Bernardo WM, editors. Projeto Diretrizes. Brasília: Conselho Federal de Medicina; 2006. p. 15–27.
Collett-Solber PF. Update in growth hormone therapy of children. J Clin Endocrinol Metabol. 2011;96(3):573–9.
Ranke MB, Grauer MI, Kistner K, Blum WF, Wollmann HA. Spontaneous adult height in idiopathic short stature. Horm Res. 1995;44:152–7.
Jorge AAL. Baixa estatura por deficiência de hormônio de crescimento: tratamento. In: Jatene FB, Nobre MRC, Bernardo WM, editors. Projeto Diretrizes. Brasília: Conselho Federal de Medicina; 2006. p. 29–36.
Guyda HJ. Four decades of growth hormone therapy for short children: what have we achieved? J Clin Endocrinol Metab. 1999;84:4307–16.
Deodati A. Review of growth hormone randomized controlled trials in children with idiopathic short stature. Horm Res Paediatr. 2011;76(3):40–2.
Saggese G. The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: results from a controlled study. J Clin Endocrinol Metab. 2011;86:1900–4.
Yanovski JA. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med. 2003;348:908–17.
Kamp GA. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation. J Clin Endocrinol Metab. 2001;86:2969–75.
Hero M. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf). 2006;64:510–3.
Acknowledgments
This work was supported by grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (The National Council for Scientific and Technological Development—CNPq) (301477/2009-4 to A.A.L.J).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Canton, A.P.M., Jorge, A.A.L. (2014). Idiopathic Short Stature: Diagnostic and Therapeutic Approach. In: Bandeira, F., Gharib, H., Golbert, A., Griz, L., Faria, M. (eds) Endocrinology and Diabetes. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8684-8_16
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8684-8_16
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-8683-1
Online ISBN: 978-1-4614-8684-8
eBook Packages: MedicineMedicine (R0)